Unknown

Dataset Information

0

Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.


ABSTRACT: The success of belatacept in late-stage clinical trials inaugurates the arrival of a new class of immunosuppressants based on costimulatory blockade, an immunosuppression strategy that disrupts essential signals required for alloreactive T-cell activation. Despite having improved renal function, kidney transplant recipients treated with belatacept experienced increased rates of acute rejection. This finding has renewed focus on costimulatory blockade-resistant rejection and specifically the role of alloreactive memory T cells in mediating this resistance. To study the mechanisms of costimulatory blockade-resistant rejection and enhance the clinical efficacy of costimulatory blockade, we developed an experimental transplant system that models a donor-specific memory CD8(+) T-cell response. After confirming that graft-specific memory T cells mediate costimulatory blockade-resistant rejection, we characterized the role of integrins in this rejection. The resistance of memory T cells to costimulatory blockade was abrogated when costimulatory blockade was coupled with either anti-VLA-4 or anti-LFA-1. Mechanistic studies revealed that in the presence of costimulatory blockade, anti-VLA-4 impaired T-cell trafficking to the graft but not memory T-cell recall effector function, whereas anti-LFA-1 attenuated both trafficking and memory recall effector function. As antagonists against these integrins are clinically approved, these findings may have significant translational potential for future clinical transplant trials.

SUBMITTER: Kitchens WH 

PROVIDER: S-EPMC3467016 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.

Kitchens W H WH   Haridas D D   Wagener M E ME   Song M M   Kirk A D AD   Larsen C P CP   Ford M L ML  

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110922 1


The success of belatacept in late-stage clinical trials inaugurates the arrival of a new class of immunosuppressants based on costimulatory blockade, an immunosuppression strategy that disrupts essential signals required for alloreactive T-cell activation. Despite having improved renal function, kidney transplant recipients treated with belatacept experienced increased rates of acute rejection. This finding has renewed focus on costimulatory blockade-resistant rejection and specifically the role  ...[more]

Similar Datasets

| S-EPMC3703766 | biostudies-literature
| S-EPMC5573634 | biostudies-literature
| S-EPMC6433496 | biostudies-literature
| S-EPMC3021718 | biostudies-literature
| S-EPMC9754003 | biostudies-literature
| S-EPMC3947453 | biostudies-literature
| S-EPMC5333968 | biostudies-literature
| S-EPMC6159972 | biostudies-literature
| S-EPMC9334669 | biostudies-literature
| S-EPMC5096415 | biostudies-literature